PriceTargets.com logo

LifeStance Health Group - LFST Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $11.50
  • Forecasted Upside: 9.73%
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 6 Buy Ratings
  • 1 Strong Buy Ratings
$10.48 As of 07/31/2026 05:00 PM ET
▼ -0.26 (-2.42%)

This chart shows the closing price for LFST by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New LifeStance Health Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LFST and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LFST

Analyst Price Target is $11.50
▲ +9.73% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for LifeStance Health Group in the last 3 months. The average price target is $11.50, with a high forecast of $15.00 and a low forecast of $8.00. The average price target represents a 9.73% upside from the last price of $10.48.

This chart shows the closing price for LFST for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 11 polled investment analysts is to moderate buy stock in LifeStance Health Group. This rating has held steady since June 2026, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
2/8/2025
  • 1 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
5/9/2025
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
8/7/2025
  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 2 sell ratings
Ratings as of
11/5/2025
  • 2 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
2/3/2026
  • 2 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/4/2026
  • 2 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
7/3/2026
  • 1 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
8/2/2026

Latest Recommendations

  • 1 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/24/2026BTIG ResearchBoost TargetBuy ➝ Buy$12.00 ➝ $15.00
7/21/2026Canaccord Genuity GroupBoost TargetBuy ➝ Buy$11.00 ➝ $13.00
7/14/2026BarclaysBoost TargetOverweight ➝ Overweight$9.00 ➝ $13.00
7/13/2026Zacks ResearchDowngradeStrong-Buy ➝ Hold
7/13/2026KeyCorpBoost TargetOverweight ➝ Overweight$11.00 ➝ $13.00
6/5/2026The Goldman Sachs GroupInitiated CoverageBuy ➝ Neutral$9.00
6/5/2026The Goldman Sachs GroupInitiated CoverageBuy ➝ Neutral$9.00
5/27/2026Weiss RatingsReiterated RatingHold (C-) ➝ Hold (C-)
5/14/2026JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$8.00 ➝ $9.00
5/8/2026BTIG ResearchBoost TargetBuy ➝ Buy$11.00 ➝ $12.00
4/27/2026Zacks ResearchUpgradeHold ➝ Strong-Buy
3/12/2026Jefferies Financial GroupUpgradeStrong-Buy
3/6/2026BarclaysBoost TargetOverweight ➝ Overweight$8.00 ➝ $9.00
2/27/2026Weiss RatingsUpgradeSell (D-) ➝ Hold (C-)
2/26/2026Canaccord Genuity GroupBoost TargetBuy ➝ Buy$9.00 ➝ $10.00
2/26/2026UBS GroupBoost TargetBuy ➝ Buy$10.00 ➝ $12.00
2/26/2026KeyCorpBoost TargetOverweight ➝ Overweight$8.00 ➝ $9.00
2/2/2026BTIG ResearchBoost TargetBuy ➝ Buy$10.00 ➝ $11.00
12/29/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/22/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/15/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/12/2025BTIG ResearchBoost TargetBuy ➝ Buy$9.00 ➝ $10.00
12/9/2025BarclaysInitiated CoverageOverweight$8.00
12/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/8/2025BarclaysUpgradeStrong-Buy
12/1/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/25/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/19/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/13/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/13/2025BMO Capital MarketsInitiated CoverageOutperform$8.00
11/7/2025UBS GroupBoost TargetBuy ➝ Buy$9.00 ➝ $10.00
11/6/2025BTIG ResearchBoost TargetBuy ➝ Buy$8.00 ➝ $9.00
11/5/2025Zacks ResearchDowngradeStrong-Buy ➝ Hold
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/7/2025Zacks ResearchUpgradeHold ➝ Strong-Buy
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
8/8/2025UBS GroupBoost TargetBuy ➝ Buy$8.50 ➝ $9.00
7/25/2025BTIG ResearchInitiated CoverageBuy$8.00
5/27/2025UBS GroupUpgradeNeutral ➝ Buy$8.50
4/8/2025KeyCorpInitiated CoverageOverweight$9.00
4/7/2025KeyCorpUpgradeStrong-Buy
4/3/2025Canaccord Genuity GroupInitiated CoverageBuy$8.00
2/28/2025William BlairReiterated RatingOutperform
12/16/2024The Goldman Sachs GroupUpgradeNeutral ➝ Buy$10.00
11/11/2024BarclaysBoost TargetUnderweight ➝ Underweight$6.00 ➝ $7.00
8/15/2024UBS GroupLower TargetNeutral ➝ Neutral$9.00 ➝ $7.50
8/9/2024BarclaysLower TargetUnderweight ➝ Underweight$8.00 ➝ $6.00
4/22/2024Morgan StanleyReiterated RatingOverweight ➝ Overweight$10.00 ➝ $10.00
3/6/2024Jefferies Financial GroupBoost TargetBuy ➝ Buy$8.00 ➝ $9.00
3/4/2024The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$8.00 ➝ $9.00
2/29/2024BarclaysBoost TargetUnderweight ➝ Underweight$7.00 ➝ $8.00
1/3/2024BarclaysInitiated CoverageUnderweight$7.00
11/22/2023The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$9.00 ➝ $8.00
11/17/2023JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$10.00 ➝ $8.00
8/10/2023JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$9.00 ➝ $10.00
5/15/2023TD CowenDowngradeOutperform ➝ Market Perform$8.00 ➝ $9.00
1/6/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight$8.00
11/15/2022The Goldman Sachs GroupLower TargetNeutral$9.00 ➝ $8.00
11/14/2022TD CowenLower TargetOutperform$10.00 ➝ $8.00
11/7/2022Jefferies Financial GroupReiterated RatingBuy$7.25
8/22/2022TD CowenLower TargetOutperform$11.00 ➝ $10.00
3/21/2022The Goldman Sachs GroupLower TargetNeutral$15.00 ➝ $10.00
3/17/2022UBS GroupDowngradeBuy ➝ Neutral$19.00 ➝ $10.00
12/17/2021Morgan StanleyLower TargetEqual Weight$15.00 ➝ $10.00
11/9/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$24.00 ➝ $12.00
9/9/2021TD CowenInitiated CoverageOutperform$18.00
8/16/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$36.00 ➝ $16.00
(Data available from 8/2/2021 forward)

News Sentiment Rating

0.84 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/4/2026
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/3/2026
  • 3 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/5/2026
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/4/2026
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/4/2026
  • 3 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/3/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2026
  • 13 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2026

Current Sentiment

  • 13 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

LifeStance Health Group logo
LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.
Read More

Today's Range

Now: $10.48
Low: $10.47
High: $10.85

50 Day Range

MA: $9.65
Low: $7.34
High: $11.58

52 Week Range

Now: $10.48
Low: $3.74
High: $11.76

Volume

2,524,932 shs

Average Volume

2,825,138 shs

Market Capitalization

$4.06 billion

P/E Ratio

174.67

Dividend Yield

N/A

Beta

1.12

Frequently Asked Questions

What sell-side analysts currently cover shares of LifeStance Health Group?

The following sell-side analysts have issued reports on LifeStance Health Group in the last twelve months: Barclays PLC, BMO Capital Markets, BTIG Research, Canaccord Genuity Group Inc., Jefferies Financial Group Inc., JPMorgan Chase & Co., KeyCorp, The Goldman Sachs Group, Inc., UBS Group AG, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for LFST.

What is the current price target for LifeStance Health Group?

0 Wall Street analysts have set twelve-month price targets for LifeStance Health Group in the last year. Their average twelve-month price target is $11.50, suggesting a possible upside of 9.7%. BTIG Research has the highest price target set, predicting LFST will reach $15.00 in the next twelve months. BMO Capital Markets has the lowest price target set, forecasting a price of $8.00 for LifeStance Health Group in the next year.
View the latest price targets for LFST.

What is the current consensus analyst rating for LifeStance Health Group?

LifeStance Health Group currently has 4 hold ratings, 6 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for LFST.

What other companies compete with LifeStance Health Group?

Other companies that are similar to LifeStance Health Group include BrightSpring Health Services, Fresenius Medical Care AG & Co. KGaA, PACS Group, Hims & Hers Health and Billiontoone. Learn More about companies similar to LifeStance Health Group.

How do I contact LifeStance Health Group's investor relations team?

The company's listed phone number is 602-767-2100 and its investor relations email address is [email protected]. The official website for LifeStance Health Group is www.lifestance.com. Learn More about contacing LifeStance Health Group investor relations.